Purihilo PN® – Hybrid HA + Polynucleotide Skin Booster | 2.5ml

Purihilo PN® – Hybrid HA + Polynucleotide Skin Booster | 2.5ml

Product Overview

Purihilo PN® is an advanced hybrid skin booster combining dual molecular weight Hyaluronic Acid (HA) with Polynucleotides (PN) in a single professional injectable formulation designed to support intensive skin hydration, regeneration and overall skin rejuvenation.

Each 2.5ml pre-filled syringe contains:

• 40mg High Molecular Weight Hyaluronic Acid

• 40mg Low Molecular Weight Hyaluronic Acid

• 25mg Polynucleotides (PN)

This provides a total of 80mg Hyaluronic Acid + 25mg Polynucleotides per 2.5ml syringe.

Developed using AETERDERM's ABEP™ Hybrid Technology, Purihilo PN® combines the hydrating and moisture-retaining properties of Hyaluronic Acid with the regenerative characteristics associated with Polynucleotides.

Unlike conventional skin boosters based solely on Hyaluronic Acid, Purihilo PN® has been developed as a hybrid formulation designed to address multiple aspects of skin quality simultaneously.

The dual molecular weight HA component supports intensive hydration, moisture retention and elasticity, while the Polynucleotide component is designed to support fibroblast activity, tissue regeneration and extracellular matrix remodelling.

The combined formulation may therefore support improvements in:

• Skin hydration

• Elasticity

• Firmness

• Skin texture

• Dermal quality

• Skin resilience

• Fine lines

• Overall skin radiance

Purihilo PN® is intended for professional skin rejuvenation rather than structural facial volumisation.

Pack Contents

Each pack contains:

• 1 × 2.5ml pre-filled syringe of Purihilo PN®

• 80mg total Hyaluronic Acid

• 25mg Polynucleotides

• Sterile needle(s), as supplied by the manufacturer

• Sterile, sealed professional-use packaging

Total Volume: 2.5ml

Always check the individual product packaging, manufacturer labelling and current Instructions for Use before administration.

Product Composition

Purihilo PN® combines two established injectable skin-rejuvenation components within a single hybrid formulation.

Dual Molecular Weight Hyaluronic Acid – 80mg / 2.5ml

Each syringe contains a total of 80mg Hyaluronic Acid, comprising:

• 40mg High Molecular Weight HA

• 40mg Low Molecular Weight HA

The combination of different molecular weight Hyaluronic Acid fractions is designed to support intensive hydration and moisture retention within the skin.

Hyaluronic Acid has a strong affinity for water and plays an important role within the extracellular matrix.

Within Purihilo PN®, the HA component is intended to support:

• Dermal hydration

• Moisture retention

• Skin elasticity

• Skin softness

• Improved skin texture

• Overall skin quality

Rather than providing the structural projection associated with a cross-linked dermal filler, the HA component is designed primarily to support skin hydration and rejuvenation.

Polynucleotides – 25mg / 2.5ml

Each syringe also contains 25mg Polynucleotides (PN).

The supplied product information describes these purified Polynucleotides as supporting regenerative processes within the skin.

Their proposed role within the formulation includes support for:

• Fibroblast activity

• Tissue regeneration

• Collagen synthesis

• Elastin synthesis

• Extracellular matrix remodelling

• Skin resilience

• Overall dermal quality

This regenerative component differentiates Purihilo PN® from conventional HA-only skin boosters.

ABEP™ Hybrid Technology

Purihilo PN® is developed using AETERDERM's ABEP™ Hybrid Technology.

According to the supplied product information, this manufacturing process is designed to stabilise the hybrid Hyaluronic Acid complex without the use of BDDE or thermal synthesis.

The objective is to maintain the functional properties of the Hyaluronic Acid while supporting prolonged hydration within the treated tissue.

The technology brings together:

• High Molecular Weight Hyaluronic Acid

• Low Molecular Weight Hyaluronic Acid

• Polynucleotides

within a single professional injectable formulation.

This creates a combined approach to skin rejuvenation, addressing hydration and regenerative support simultaneously rather than relying upon a single mechanism.

Dual-Action Skin Rejuvenation

One of the principal characteristics of Purihilo PN® is the combination of Hyaluronic Acid hydration and Polynucleotide regenerative support.

Hyaluronic Acid

The dual molecular weight HA component is designed primarily to support:

• Intensive hydration

• Moisture retention

• Skin elasticity

• Skin softness

• Improved texture

• Overall skin quality

Polynucleotides

The PN component is designed to support:

• Fibroblast activity

• Tissue repair and regeneration

• Collagen production

• Elastin production

• Extracellular matrix remodelling

• Dermal resilience

Together, these components create a hybrid treatment concept designed to support both immediate hydration and progressive improvement in overall skin quality.

Skin Hydration

Adequate hydration plays an important role in the appearance, elasticity and overall quality of the skin.

The 80mg dual molecular weight HA complex within Purihilo PN® is designed to provide intensive hydration while helping the skin retain moisture.

Improved hydration may contribute to:

• Softer-feeling skin

• Improved elasticity

• Smoother-looking texture

• Improved radiance

• Reduction in the appearance of dehydration-related fine lines

• Improved overall skin quality

The product is therefore positioned as a skin-quality treatment rather than a conventional volumising dermal filler.

Polynucleotide Regenerative Support

Polynucleotides have become increasingly incorporated into professional regenerative aesthetic protocols where improvement in skin quality is the primary treatment objective.

Within Purihilo PN®, the 25mg PN component is designed to complement the hydrating effects of Hyaluronic Acid.

The supplied product information describes PN as supporting fibroblast activity and processes associated with:

• Collagen production

• Elastin production

• Tissue regeneration

• Extracellular matrix remodelling

These processes may contribute to progressive improvements in skin firmness, elasticity, texture and resilience during an appropriate treatment course.

Key Benefits

• Advanced hybrid HA + PN skin booster

• 2.5ml pre-filled syringe

• 80mg total Hyaluronic Acid

• 40mg High Molecular Weight HA

• 40mg Low Molecular Weight HA

• 25mg Polynucleotides

• Combines hydration and regenerative skin support

• Provides intensive dermal hydration

• Supports prolonged moisture retention

• Supports fibroblast activity

• Supports collagen production

• Supports elastin production

• Encourages tissue regeneration

• Supports extracellular matrix remodelling

• Helps improve skin elasticity

• Helps improve skin firmness

• Supports smoother-looking skin

• May improve the appearance of fine lines

• Helps improve skin texture

• Supports skin radiance

• Helps improve overall skin quality

• Designed for regenerative aesthetic protocols

• Does not primarily function as a structural dermal filler

• Suitable for professionally selected face and body treatment areas

• Intended for appropriately qualified professional use

Common Treatment Areas

Purihilo PN® may be incorporated into professional skin-rejuvenation protocols targeting areas demonstrating dehydration, reduced elasticity or deterioration in overall skin quality.

Potential treatment areas described in the supplied information include:

• Full face

• Neck

• Décolletage

• Hands

• Areas demonstrating reduced skin elasticity

• Areas of skin laxity

• Areas requiring general skin rejuvenation

Treatment area suitability should always be determined following assessment of the patient's anatomy, skin condition, medical history and individual treatment objectives.

Always follow the manufacturer's current Instructions for Use regarding approved indications, treatment areas, administration technique, treatment depth and product volume.

Purihilo PN® vs Traditional HA Skin Boosters

Traditional Hyaluronic Acid skin boosters primarily focus on improving skin hydration and moisture retention.

Purihilo PN® combines this hydrating approach with a Polynucleotide component.

Traditional HA Skin Booster

Treatment objectives commonly focus on:

• Hydration

• Moisture retention

• Skin smoothness

• Elasticity

• General skin quality

Purihilo PN®

The hybrid formulation is designed to support:

• Intensive hydration

• Moisture retention

• Fibroblast activity

• Collagen production

• Elastin production

• Tissue regeneration

• Extracellular matrix remodelling

• Skin elasticity

• Skin firmness

• Overall skin quality

Purihilo PN® therefore provides a combined hydration + regenerative support approach within a single 2.5ml formulation.

Purihilo PN® vs Structural Dermal Fillers

Purihilo PN® should not be considered equivalent to a conventional cross-linked Hyaluronic Acid dermal filler.

Structural HA Dermal Fillers

These products are typically designed to provide:

• Immediate physical volume

• Projection

• Structural support

• Facial contouring

• Correction of selected wrinkles and folds

Purihilo PN®

Purihilo PN® is designed primarily to support:

• Skin hydration

• Skin regeneration

• Improved elasticity

• Improved firmness

• Improved skin texture

• Improved skin resilience

• Progressive improvement in overall skin quality

Its primary objective is therefore skin-quality improvement rather than structural facial augmentation.

Recommended Treatment Course

The supplied product information describes Purihilo PN® as being commonly incorporated into a course of 3–4 treatment sessions.

A referenced treatment approach is:

• Initial Course: 3–4 treatments

• Treatment Interval: Approximately every 2–3 weeks

• Maintenance: Approximately every 4–6 months, or as clinically indicated

These intervals should not be interpreted as a universal protocol.

The appropriate number of sessions, treatment interval and maintenance schedule should always be individually determined according to:

• Patient age

• Baseline skin condition

• Degree of dehydration

• Skin elasticity

• Tissue quality

• Treatment area

• Previous aesthetic treatments

• Clinical response

• Individual treatment objectives

Always follow the manufacturer's current Instructions for Use and professional guidance where these differ from commonly referenced treatment protocols.

Professional Treatment Considerations

Purihilo PN® is intended for administration by appropriately qualified and trained professionals with suitable knowledge of injectable skin-rejuvenation procedures.

Treatment planning should include:

• Comprehensive patient consultation

• Review of medical history

• Assessment of skin quality

• Assessment of tissue condition

• Evaluation of the proposed treatment area

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects

• Appropriate documented informed consent

The appropriate treatment technique, depth, product volume and distribution should be determined according to the patient's anatomy, skin condition, professional assessment and manufacturer's current Instructions for Use.

Purihilo PN® should not be administered using a generic treatment protocol without appropriate consideration of individual anatomy and patient-specific factors.

Results & Treatment Outcomes

Purihilo PN® is designed to provide a combination of hydration and progressive regenerative skin support.

The Hyaluronic Acid component supports hydration, while the Polynucleotide component is intended to support longer-term regenerative processes within the treated tissue.

Potential improvements may include:

• Increased skin hydration

• Improved moisture retention

• Improved skin elasticity

• Improved firmness

• Smoother-looking skin

• Improved skin texture

• Reduction in the appearance of fine lines

• Improved skin radiance

• Improved skin resilience

• Overall improvement in skin quality

Some hydration-related effects may become apparent relatively early, while regenerative changes associated with tissue remodelling are expected to develop progressively.

The supplied product information indicates that improvements may become noticeable over several weeks, with continued changes occurring throughout the treatment course.

A complete professionally designed treatment course may therefore be recommended to maximise the intended skin-quality benefits.

Individual outcomes will vary according to:

• Patient age

• Baseline skin condition

• Treatment area

• Number of sessions

• Treatment interval

• Practitioner technique

• Lifestyle

• Skin ageing

• Individual biological response

Maintenance treatment may subsequently be considered following professional reassessment.

Storage & Handling

Purihilo PN® should be stored and handled according to the manufacturer's current Instructions for Use and the information supplied with the original product.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect the product from inappropriate environmental exposure.

• Inspect the syringe and packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Maintain appropriate aseptic handling procedures.

• Do not use if the sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

Each syringe is intended for single-patient professional use according to the manufacturer's instructions.

Important Information

Purihilo PN® is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Relevant anatomy

• Injectable skin-rejuvenation techniques

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Adverse-event recognition

• Appropriate complication management

Patient Assessment

Treatment should only proceed following appropriate patient consultation, medical assessment and informed consent.

Practitioners should consider:

• Patient medical history

• Previous aesthetic treatments

• Skin condition

• Treatment-area anatomy

• Allergies and hypersensitivities

• Current medications where relevant

• Active infection or inflammation

• Relevant underlying medical conditions

• Individual treatment objectives

• Manufacturer-defined contraindications

Contraindications & Precautions

The information supplied does not provide a complete manufacturer-defined contraindication list.

Practitioners should therefore refer directly to the current Purihilo PN® manufacturer Instructions for Use before treatment rather than relying on a generic skin-booster contraindication list.

Treatment should not proceed where product integrity, authenticity or sterility is in doubt.

Potential Treatment Reactions

As with injectable aesthetic procedures, temporary local treatment reactions may occur.

The exact adverse-event profile should be confirmed from the current manufacturer Instructions for Use.

Practitioners should provide patients with appropriate aftercare information and clear guidance regarding symptoms requiring professional or urgent medical assessment.

Always consult the manufacturer's current Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, administration and potential adverse events.

For appropriately qualified professional use only.